louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05876650: Pilates Exercises v/s Yoga on Rounded Shoulders
Official title: Compariso of Pilates Exercises and Yoga on Rounded Shoulders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Weakness, Muscle
Muscle Tightness
Range of Motion
Pain
Heart Rate
SpO2
Sleep Quality
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-05-25
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To Compare the effects of Pilates exercises an yoga on rounded shoulders

Detailed description: Pilates exercises and Yoga are two effective treatments for correcting RSP. In Pilates each exercise is conducted in more than one times usually three to five hence exposing the body to different and new muscular and kinesthetic challenges. On the other hand Yoga is a process in which the joints and muscles operate together in a systematic and automatic manner where each pose is sustained for a period of time. Several literatures support the belief that Pilates exercises and Yoga are effective treatments for RSP correction, as well as improving sleep quality, heart rate and SpO2 First, The participants will be divided into two groups, for Pilates exercises and Yoga. Honor wristbands will be distributed and Exercises will be demonstrated to each group. Explanation of using Honor band will be given. Measurements will be taken before the intervention including cervical ROM. shoulder ROM at baseline, 2nd week and 4th week. while heart rate, SpO2 immediately after the session. Sleep quality prior the intervention, 2nd and 4th week. Patients will do the exercises 3 times per week for 4 consecutive weeks.

Eligibility criteria: Inclusion Criteria:

* Patients with rounded shoulders who achieve more than 2.5 cm in table top test.

Exclusion Criteria:

* Patients with a positive history of trauma, fracture or surgery of the cervical spine or shoulder.
* Neck pain with radiation to the arm and upper extremity.
* Diagnosed cases of torticollis and scoliosis.
* Patient with any serious underlying pathology that influence the mobility of upper limb
* History of osteoporosis, any heart disease

Primary outcomes:
measure: Rigid transparent plastic protractor
timeFrame: 2nd week and 4th week
Secondary outcomes:
measure: Neck diability Index
timeFrame: 4th week
measure: Goniometer
timeFrame: 2nd week and 4th week
measure: The Shoulder Pain and Disability Index
timeFrame: 4th week
measure: Honor Band 5 Smart Wristband Fitness Tracker
timeFrame: 2nd week and 4th week
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Riphah International University
Study officials:
affiliation: Riphah College of Rehabilitation and Allied Health Sciences, Riphah International University
name: Muhammad Affan Iqbal, PHD*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06092450: Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer
Official title: Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome From Preoperative CT in Muscle Invasive Bladder Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bladder Cancer
Keywords: Tomography, X-ray computed
Muscle-invasive bladder cancer
Radiomics
Deep Learning
Lead sponsor: First Affiliated Hospital of Chongqing Medical University
Sponsor class: OTHER
First posted: 2023-10-23
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with pathologically confirmed MIBC who underwent radical cystectomy

Brief summary: Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis. This study was aimed to develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC.


Eligibility criteria: Inclusion Criteria:

* patients with pathologically confirmed MIBC after radical cystectomy;
* contrast-CT scan less than two weeks before surgery;
* complete CT image data and clinical data.

Exclusion Criteria:

* patients who received neoadjuvant therapy;
* non-urothelial carcinoma;
* poor quality of CT images;
* incomplete clinical and follow-up data.

Primary outcomes:
measure: Overall survival（OS）
timeFrame: up to 10 years
measure: Recurrence free survival（RFS)
timeFrame: up to 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Department of Urology, The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
Study officials:
References:
Clinical trial NCT02790255: BRown Fat Activity Measurement With Infrared imaginG tHermography andThermogenesis - the BRIGHT Study
Official title: BRown Fat Activity Measurement With Infrared imaginG tHermography and Thermogenesis - the BRIGHT Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Energy Expenditure
Obesity
Adipose Tissue, Brown
Lead sponsor: Singapore Institute of Food and Biotechnology Innovation
Sponsor class: OTHER_GOV
Collaborators: name: Institute for Infocomm Research
First posted: 2016-06-03
Enrollment: 20
Sex: MALE
Minimum age (years): 21
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The whole body calorimeter is sensitive enough to reliably measure cold-induced thermogenesis as a surrogate marker of brown adipose tissue (BAT) activation.

The infrared (IR) energy flux from activated BAT can be accurately imaged and quantified using an IR imaging device, and that this IR energy output may be correlated to the increased energy expenditure quantified by the whole body calorimeter.

Detailed description: The recent rediscovery of functional brown adipose tissue (BAT) in healthy adults has opened up the exciting possibility of manipulating BAT for obesity management, and it is imperative to develop BAT imaging modalities that are non-invasive and safe for repeated use. Given that heat is a specific end-product of uncoupling protein-1 (UCP-1)-mediated BAT, this study examines whether surface body temperature assessed using infrared (IR) thermography can be a non-invasive measure to accurately and precisely predict brown adipose tissue (BAT) activation upon cold stimulation, which involves verifying an semi-automated method for characterizing thermal images. In addition, this study also aims to validate the use of a whole-body calorimeter to pick up changes in energy expenditure upon cold-induced thermogenesis. Lean, healthy male volunteers will be recruited. Thermal imaging of cervical-supraclavicular BAT will be done using an IR camera to assess changes in BAT activation. Blood samples will also be drawn at regular intervals to track changes in serum metabolites upon BAT activation. All in all, this study hopes to provide more supporting evidence that IR thermography is a viable imaging modality that is non-invasive, safe and reproducible of studying BAT activity.

Eligibility criteria: Inclusion Criteria:

* Male
* Ethnic Chinese
* Age between 21 to 35 years
* Body Mass Index 18.5 to 22.9
* Normal resting blood pressure \~120/80 mmHg
* Normal fasting blood glucose level \<5.5 mmol/L

Exclusion Criteria:

* Do not train for or partake in competitive sports
* Do not have any major diseases
* Not on any prescribed medication

Primary outcomes:
measure: Temperature at cervical-supraclavicular region
timeFrame: 45 minutes cold exposure
Secondary outcomes:
measure: Energy expenditure during cold exposure
timeFrame: 45 minutes cold exposure
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06730555: Advancing Equitable Access to HIV/HCV Testing for People Who Inject Drugs (PWID)
Official title: Project ACCESS: Advancing Equitable Access to HIV/HCV Testing Through Structural Transformation in Syringe Services Programs: A Cluster Randomized Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: HIV Infections
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2024-12-12
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who inject drugs (PWID).


Eligibility criteria: Inclusion Criteria:

* SSPs must:

  1. be operating in an Ending the HIV Epidemic (EHE) or Centers for Disease Control and Prevention (CDC) determined vulnerable jurisdictions;
  2. serve at least 300 unique participants per year;
  3. not currently offer opt-out HIV/HCV testing;
  4. be capable and willing to prospectively collect aggregated, site-level data on the number of participants who are: i) offered HIV/HCV screening, ii) completed these tests, and iii) linked to care, as well as provide participant demographics;
  5. have key staff that consent to participate in study surveys, qualitative interviews and practice facilitation throughout the study.

Exclusion Criteria:

* SSPs must not:

  1. currently receive or have received Frontline Communities in the United States (FOCUS) funding;
  2. have already implemented opt-out HIV/HCV testing.

Primary outcomes:
measure: Number of SSP participants reached
timeFrame: up to 18 months
measure: Adopotion
timeFrame: up to 6 months
Secondary outcomes:
measure: Number of SSP participants reached after the intervention
timeFrame: up to 30 months
measure: Number of racial minorities reached
timeFrame: up to 18 months
measure: Number of gender minorities reached
timeFrame: up to 18 months
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Tyler Bartholomew, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01534650: Movement Disorder Quantification Algorithm Development
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Essential Tremor
Keywords: motion sensors
tremor
bradykinesia
gait
balance
dyskinesia
Lead sponsor: Great Lakes NeuroTechnologies Inc.
Sponsor class: INDUSTRY
First posted: 2012-02-17
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of Northeastern Ohio with a movement disorder such as Parkinson's disease or essential tremor.

Brief summary: The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such as tremor, bradykinesia (slowed movements), dyskinesias (sudden, involuntary movements), gait, and balance during standardized tasks and/or activities of daily living.


Eligibility criteria: Inclusion Criteria:

* Aged 18 years or older
* Clinical diagnosis of idiopathic Parkinson's disease or essential tremor
* Able to provide informed consent

Exclusion Criteria:

* Significant medical or psychiatric illness
* Not capable of following the required clinical instructions
* Serious medical conditions that compromise safety

Primary outcomes:
measure: Processed kinematics
timeFrame: During assessment
Secondary outcomes:
Other outcomes:
Locations:
city: Valley View
country: United States
facility: Great Lakes NeuroTechnologies Inc. Movement Disorders Laboratory
state: Ohio
Study officials:
affiliation: Great Lakes NeuroTechnologies Inc.
name: Dustin A Heldman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01552850: Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
Official title: An Open-Label, Single-Dose, Randomized, Crossover Pharmacokinetics And Relative Bioavailability Study Of Three Modified 40 Mg Oxycodone Formulations Compared With 40 Mg Pf-00345439 Capsule Formulation In Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pain
Keywords: pharmacokinetics
relative bioavailability
oxycodone
Lead sponsor: PainT
Sponsor class: UNKNOWN
First posted: 2012-03-13
Enrollment: 18
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of four PF-00345439 formulations and oxycodone in solution

Detailed description: This study will estimate the PK and relative bioavailability of oxycodone following single oral 40-mg doses of 3 modified PF-00345439 Formulations B, C, and D compared with the reference Formulation A under fed conditions.

Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive

Exclusion Criteria:

* Evidence or history of clinically significant diseases

Primary outcomes:
measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) (if data permit, otherwise Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUClast]) of oxycodone.
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Secondary outcomes:
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of oxycodone, as data permit.
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax) of oxycodone, as data permit.
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
measure: Plasma Decay Half-Life of oxycodone, as data permit.
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
measure: Concentration at time 24 hours (C24) of oxycodone, as data permit.
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
measure: Adverse events, vital signs and laboratory parameters.
timeFrame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT03423550: Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis
Official title: Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis by Using New Sample Preparation and Detection Technique
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tuberculosis
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2018-02-06
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Patients who are clinically suspected with pulmonary tuberculosis, tuberculosis meningitis, tuberculosis peritonitis, tuberculosis pleurisy
* The participants will undertake conventional examination including AFB culture / smear and X-pert TB assay and new assay

Brief summary: This study evaluates new technique for diagnosis of tuberculosis. Among patients who are suspected with tuberculosis, participants will be tested conventional method including Xpert TB/RIF assay, and new diagnostic technique using homobifunctionalImidoesters compounds.


Eligibility criteria: Inclusion Criteria:

* Patients who are suspected with pulmonary tuberculosis, tuberculosis meningitis, tuberculosis peritonitis, tuberculosis pleurisy

Exclusion Criteria:

* Under 18 years

Primary outcomes:
measure: The effectiveness of new diagnostic technique
timeFrame: An average of 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine
Study officials:
References:
Clinical trial NCT00631150: A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
Official title: A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Epilepsy
Keywords: Levetiracetam
Keppra
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2008-03-07
Enrollment: 35
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients in community-based practices correspond to the 25% of patients who need a first add-on drug when not controlled by their standard monotherapy drug. This was a therapeutic use trial in which the population corresponds more closely to that seen in daily clinical practice.


Eligibility criteria: Inclusion Criteria:

* partial onset seizures with or without secondary generalisation with epilepsy.

Exclusion Criteria:

* hypersensitivity to levetiracetam or other pyrrolidone derivatives or to any of the excipients.

Primary outcomes:
measure: Safety and the tolerability of Keppra in a broad population of patients.
Secondary outcomes:
measure: Obtain further information about optimal daily dose.
Other outcomes:
Locations:
Study officials:
affiliation: +1 877 822 9493 (UCB)
name: UCB Clinical Trial Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00000250: Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
Official title: Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Substance-Related Disorders
Keywords: nitrous oxide
choice
subjective effects
pain
analgesia
reinforcer
healthy volunteer
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 12
Sex: ALL
Minimum age (years): 21
Maximum age (years): 32
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To evaluate: cold water immersion modulates the reinforcing effects of nitrous oxide in healthy volunteers.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Subject's choice of intervention
timeFrame: After sampling trials
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago, Anesthesia & Critical Care
state: Illinois
Study officials:
affiliation: University of Chicago
name: James Zacny, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Experimentall Clinical Psycopharmacoly 1995, 3(2):148-155
Clinical trial NCT05771350: Online Hemodiafiltration Versus Hemodialysis in Removal of Indoxyl Sulfate in Chronic Hemodialysis Patients
Official title: Hemodiafiltration Versus Hemodialysis in Removal of Indoxyl Sulfate in Chronic Hemodialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodialysis
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2023-03-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this study aimed to compare the removal of indoxyl sulphate between hemodiafiltration, high flux hemodialysis and low flux hemodialysis


Eligibility criteria: Inclusion Criteria:

* maintenance hemodialysis patients aged more than 18 years

Exclusion Criteria:

* active illnesses, hospitalization, malignancy

Primary outcomes:
measure: dialytic removal of indoxyl sulpahte
timeFrame: one month when all samples were collected
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00836550: Video-based Counseling & Rapid HIV Testing for Teens
Official title: An RCT to Evaluate the Effectiveness of an Emergency Department Based Multimedia HIV Testing Model in Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV
HIV Infections
Keywords: HIV
HIV knowledge measure
Teen HIV testing
HIV Seronegativity
Lead sponsor: North Bronx Healthcare Network
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2009-02-04
Enrollment: 200
Sex: ALL
Minimum age (years): 15
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study evaluated the educational effectiveness of a youth-friendly pre-test video (derived from a previous qualitative study) and compared it with in-person HIV pre-test counseling. A convenience sample of 200 medically stable individuals between the ages of 15 and 21 presenting to an urban ED were recruited to participate in this study and randomized into 2 groups. Individuals were eligible if they were English-speaking, sexually active and able to consent. All participants completed a sexual risk factor and demographic survey. Group 1 completed a validated pre-test knowledge measure, viewed the HIV education video then completed a post-test knowledge measure. Group 2 completed the same knowledge measures, but received pre-test HIV counseling from a trained public health advocate. HIV testing was optional


Eligibility criteria: Inclusion Criteria:

* 15-21 year old
* sexually active
* English-Speaking

Exclusion Criteria:

* medically unstable

Primary outcomes:
measure: Knowledge of HIV
timeFrame: 2 months
Secondary outcomes:
measure: Consent to HIV testing
timeFrame: 2 months
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Jacobi Medical Center
state: New York
Study officials:
affiliation: Jacobi Medical Center/ Albert Einstein College of Medicine
name: Yvette Calderon, MD MS
role: PRINCIPAL_INVESTIGATOR
References: